IM14.1-14 | Obesity — Graded Quiz

Correct. IDF 2005 criteria for Asian women use a central obesity threshold of waist ≥80 cm (not ≥88 cm). This patient's waist of 85 cm exceeds this threshold. She also meets 3 of the 4 remaining criteria: triglycerides ≥150 (175 mg/dL — met), BP ≥130/85 (138/88 — met), and fasting glucose ≥100 mg/dL (102 — met). HDL ≥50 mg/dL is the cut-off for women; her HDL of 44 mg/dL also meets this criterion. She actually meets all 4 remaining criteria. Metabolic syndrome is confirmed.

A critical error in metabolic syndrome assessment in Indian women: using Western waist cut-off (88 cm) instead of IDF Asian (80 cm). Using the wrong cut-off misses central obesity and produces a false negative diagnosis.

IDF Asian criteria use waist ≥80 cm for women (not ≥88 cm — that is the NCEP-ATP III Western threshold). At 85 cm, central obesity is present. She meets all 4 remaining criteria: TG ≥150, HDL <50, BP ≥130/85, and FBG ≥100. Applying Western waist cut-offs to South Asian women is a common clinical error that leads to under-diagnosis of metabolic syndrome.

Correct. The standard measurement of waist circumference is taken with a non-elastic tape at the mid-point between the lowest rib margin (inferior costal margin) and the superior border of the iliac crest, at the end of normal expiration. The subject should stand relaxed and breathe normally. This is the WHO-recommended method and is used in IDF criteria. Measuring at the umbilicus is unreliable because the umbilicus position varies with fat distribution.

Waist circumference technique: non-elastic tape, mid-point between lowest rib and iliac crest, end of normal expiration, standing relaxed. Cut-offs (Asian-Indian): men ≥90 cm, women ≥80 cm. BMI measures total adiposity; waist circumference specifically measures central (visceral) adiposity — a stronger predictor of cardiometabolic risk.

Waist circumference is measured at the mid-point between the lower rib margin and iliac crest at the end of normal expiration. Measuring at the umbilicus overestimates waist circumference in those with panniculus (apron abdomen) and underestimates it if the umbilicus is displaced. The correct landmark and phase of respiration are examination competencies tested in clinical skills assessments.

Correct. The 5% weight loss threshold is the minimum clinically meaningful target — it improves HbA1c, lipids, blood pressure, and hepatic steatosis. At 3.6% loss after 3 months, this patient has not reached the target. With BMI ≥27.5 kg/m² and a major comorbidity (type 2 diabetes), pharmacotherapy is now indicated after 3–6 months of inadequate lifestyle response. GLP-1 receptor agonists (semaglutide, liraglutide) are preferred given their dual benefit on weight and glycaemia. Bariatric surgery thresholds are BMI ≥32.5 with comorbidity — not yet met.

Stepwise obesity management: lifestyle modification (all patients, first-line) → pharmacotherapy (BMI ≥27.5 with comorbidity or ≥32.5 without, after 3–6 months inadequate response, ≥5% target) → bariatric surgery (BMI ≥32.5 with comorbidity or ≥37.5 without). The 5% weight loss target is the minimum for clinical benefit.

After 3 months of lifestyle modification without achieving ≥5% weight loss, and with BMI ≥27.5 plus type 2 diabetes, pharmacotherapy is indicated. The 5% threshold marks clinically meaningful improvement in cardiometabolic outcomes. Bariatric referral requires BMI ≥32.5 with comorbidity (Asian-Indian threshold) — this patient does not yet meet it. GLP-1 RAs are the preferred class for this patient given concurrent T2DM and cardiovascular risk.

Correct. In a reproductive-age woman, the triad of oligomenorrhoea/irregular cycles, hirsutism, and insulin resistance (acanthosis nigricans, pre-diabetic fasting glucose) is the hallmark of polycystic ovary syndrome (PCOS). PCOS is the most common endocrine condition in women aged 18–44 and a major secondary contributor to obesity in this age group. The diagnostic Rotterdam criteria require ≥2 of: irregular cycles, clinical/biochemical hyperandrogenism, polycystic ovaries on USS. Cushing syndrome would require violaceous striae, moon facies, and hypertension to be a leading diagnosis.

PCOS as secondary obesity cause in women: Rotterdam criteria (≥2 of 3 — oligomenorrhoea, hyperandrogenism, polycystic ovaries). Associated with insulin resistance (acanthosis nigricans), metabolic syndrome, and T2DM risk. First-line investigation: pelvic ultrasound + LH/FSH ratio + free androgen index + fasting insulin.

In a reproductive-age woman with oligomenorrhoea, hirsutism, acanthosis nigricans (insulin resistance), and weight gain, PCOS is the primary differential. It is the most common endocrine cause of obesity in women of reproductive age. PCOS drives insulin resistance independently of BMI, and obesity worsens PCOS severity — a bidirectional relationship. Cushing syndrome requires a more specific phenotype (violaceous striae, moon facies, proximal myopathy, hypokalaemia).

Correct. The causal pathway from visceral adiposity to type 2 diabetes is the best established: visceral adipocytes release free fatty acids and pro-inflammatory adipokines (TNF-α, IL-6, resistin), which cause hepatic insulin resistance (impaired first-pass insulin extraction → hepatic glucose overproduction) and peripheral insulin resistance (GLUT-4 downregulation in muscle). Weight loss reverses insulin resistance in a dose-dependent manner, which is the gold standard evidence for causation. Indian men accumulate visceral fat preferentially, amplifying this pathway at lower BMI.

Natural history of obesity complications: T2DM (causal — visceral fat insulin resistance, strongest reversibility evidence), OSA (mechanical + inflammatory), NASH/cirrhosis, HTN (RAAS activation + leptin-mediated sympathetic stimulation), dyslipidaemia (atherogenic: raised TG, low HDL, small-dense LDL), PCOS, osteoarthritis, obesity-related cancers (endometrial, breast, colorectal).

The causal chain from visceral adiposity to T2DM is the strongest and most completely characterised in obesity medicine: excess visceral fat → FFA and adipokine release → hepatic + peripheral insulin resistance → impaired glucose homeostasis. This is directly reversible with weight loss, establishing causation. OSA is both mechanical (upper airway fat) and inflammatory; the other options are associative or partially mechanical.

Correct. Elevated ALT (indicating hepatocellular injury) in the context of central obesity, hypertriglyceridaemia, and low HDL — the metabolic syndrome pattern — is the clinical indicator for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). A liver ultrasound can detect hepatic steatosis (bright liver appearance on USS), and the finding drives further management including fibroscan (FibroScan) or liver biopsy if steatohepatitis is suspected. ALT elevation to 2× ULN in this context should not be attributed to another cause without imaging.

MASLD (NAFLD/NASH) investigation: raised ALT with metabolic syndrome pattern → liver USS (bright liver, steatosis) → FIB-4 score (age × AST / platelet × ALT) → FibroScan (transient elastography) if fibrosis suspected. Weight loss is the only proven treatment — 10% weight loss reverses steatohepatitis in most cases.

Raised ALT in the context of metabolic syndrome features (central obesity, hypertriglyceridaemia, low HDL) signals MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD/NASH). Liver ultrasound is indicated to confirm steatosis. Isolated cholesterol elevation or pre-diabetes alone do not mandate liver imaging; it is the metabolic syndrome pattern with hepatocellular injury markers that drives this investigation.

Correct. Prevention levels: Primary prevention prevents obesity before it develops — population-level strategies: school and workplace nutrition education, built environment design (parks, cycle paths, walkable neighbourhoods), taxes on sugar-sweetened beverages, food labelling regulations. Secondary prevention identifies overweight individuals early and intervenes before complications develop — clinical and community screening at BMI ≥23 (Asian-Indian overweight), early lifestyle counselling. Tertiary prevention manages established obesity-related complications to limit morbidity — management of T2DM, OSA, NASH, cardiovascular disease in obese patients.

Obesity prevention levels: Primary (healthy-weight populations → nutrition literacy, built environment, food policy), Secondary (overweight → early detection, lifestyle counselling, community health workers), Tertiary (obese with complications → pharmacotherapy, bariatric surgery, complication management). India's NP-NCD guidelines emphasise primary and secondary prevention at the community level.

Correct prevention mapping: Primary = prevent obesity from developing (community nutrition education, built environment, food policy); Secondary = early identification and intervention in overweight individuals before complications (screen at BMI ≥23, lifestyle counselling); Tertiary = limit morbidity from established obesity-related complications (manage T2DM, OSA, cardiovascular disease). Pharmacotherapy and bariatric surgery are primarily tertiary-level interventions.

Correct. Obstructive sleep apnoea (OSA) is a major complication of obesity, affecting up to 45% of patients with BMI >35. Diagnosis requires measurement of the Apnoea-Hypopnoea Index (AHI): mild OSA = AHI 5–14, moderate = 15–29, severe ≥30/hour. The gold standard is overnight polysomnography (PSG) in a sleep laboratory, but home sleep apnoea testing (HSAT/level 3 or 4 portable monitor) is acceptable for patients with high pre-test probability without confounding conditions. Nocturnal oximetry alone is insufficient — it cannot quantify AHI or distinguish obstructive from central events.

OSA in obesity: present in up to 45% with BMI >35 in Indian clinical settings. Investigate with polysomnography (AHI diagnostic). Complications: refractory hypertension, pulmonary hypertension, atrial fibrillation, cognitive impairment, increased perioperative risk. Treatment: CPAP + weight loss. OSA is a bariatric surgery indication.

OSA diagnosis requires AHI quantification by polysomnography or validated HSAT — not oximetry or symptom score alone. The Epworth scale assesses severity of sleepiness but is not diagnostic. OSA in obesity is caused by pharyngeal fat deposition narrowing the upper airway, impaired neuromuscular tone, and reduced functional residual capacity from truncal obesity. Treatment is CPAP; weight loss reduces OSA severity and can achieve remission in mild-moderate disease.

Correct. Orlistat causes GI side effects including steatorrhoea (oily stools), faecal urgency, and in some patients severe diarrhoea. If diarrhoea occurs within the absorption window for the oral contraceptive pill (typically 3–4 hours post-dose), oral contraceptive absorption may be incomplete, potentially reducing contraceptive efficacy. The UK MHRA guidance recommends that women on oral contraceptives who experience severe diarrhoea with orlistat should use an additional non-oral contraceptive method during the episode and for 7 days after. Additionally, orlistat reduces fat-soluble vitamin (A, D, E, K) absorption — a multivitamin at bedtime (away from orlistat doses) is recommended.

Orlistat counselling: (1) GI side effects (steatorrhoea, urgency) are common and expected, especially with high-fat meals; (2) fat-soluble vitamin depletion — supplement with multivitamin 2 hours before or after orlistat; (3) OCP interaction via diarrhoea — use additional contraception; (4) it is a pancreatic lipase inhibitor, not a centrally-acting agent — no sympathomimetic or cardiac risk.

Orlistat's key interaction with the OCP is not a direct pharmacokinetic interaction but a pharmacodynamic one: orlistat-induced diarrhoea can impair OCP absorption if it occurs within the absorption window, reducing contraceptive efficacy. Women should be advised to use additional contraception during diarrhoeal episodes. The fat-soluble vitamin point (option A) is also correct as a counselling point but is not the MOST important interaction specifically for this patient taking the OCP.

Correct. The public health rationale for structural interventions (taxes, labelling, zoning) is that individual choice occurs within a choice architecture shaped by the food environment. Ultra-processed, calorie-dense foods are cheaper, more widely available, more aggressively marketed, and designed to be more palatable than whole foods — making the unhealthy choice the default. Structural measures shift this default: a sugar tax raises the relative price of SSBs across the entire population; front-of-pack labelling changes which products people reach for by default. Individual counselling reaches motivated individuals in healthcare settings; population measures shift the baseline for everyone.

Health promotion principle: structural/environmental interventions have the largest population impact for obesity because they shift the default for everyone (healthy choice = easy choice). Individual counselling is effective for motivated individuals but cannot reach population scale. India's approach includes SSB taxes, FSSAI front-of-pack labelling, school canteen guidelines, and the Fit India Movement.

The public health rationale is not about individual inability but about choice architecture: when the obesogenic environment makes unhealthy choices easy and healthy choices effortful, structural interventions are needed to shift the default for the entire population. Individual-level counselling only reaches patients in healthcare settings; population measures (taxes, labelling, built environment) shift the default for everyone, including those who never consult a doctor.

Correct. Congenital leptin deficiency (homozygous LEP mutation) is a rare but clinically important monogenic cause of severe childhood-onset obesity and hyperphagia. Because the condition results from absent leptin signalling (not receptor defect), exogenous recombinant leptin replacement (metreleptin) is remarkably effective — it restores satiety signalling, dramatically reduces hyperphagia, and results in substantial weight loss. This is one of the few cases in obesity medicine where a targeted molecular treatment directly addresses the underlying cause. MC4R mutations (the most common monogenic obesity) are currently treated symptomatically; setmelanotide (MC4R pathway agonist) is now licensed for some rare MC4R pathway defects.

Treatable monogenic obesity: leptin deficiency (LEP mutation) → metreleptin; leptin receptor deficiency (LEPR) → no effective targeted therapy yet; MC4R pathway defects → setmelanotide (baroreceptor agonist, licensed 2022 for POMC/PCSK1/LEPR deficiency). Monogenic obesity = childhood-onset severe obesity + hyperphagia + family clustering. Genetic testing changes management.

Congenital leptin deficiency is the paradigm monogenic obesity where targeted treatment (metreleptin replacement) is transformative. Bariatric surgery is NOT the primary treatment for a correctable molecular defect. GLP-1 RAs work on appetite signalling downstream of leptin and can still have some efficacy. The teachable moment: recognising rare but treatable monogenic obesity subtypes requires pattern recognition (childhood-onset severe obesity + hyperphagia + family history + low or absent leptin).

Correct. The highest-quality evidence for dietary weight loss consistently shows that an energy deficit of 500–750 kcal/day produces 0.5–0.75 kg weight loss per week regardless of macronutrient composition (low-fat, low-carbohydrate, Mediterranean, DASH — all equivalent at matched caloric deficit). Eliminating a single food group (rice, fruit juice) is less effective than a sustainable overall caloric reduction. However, the elimination of fruit juice (option C) would be the most impactful single food swap because four glasses of fruit juice may contribute 400–600 kcal/day of liquid sugar with minimal satiety. The question asks for the single modification with the strongest evidence BASE — which is caloric deficit, not any specific food restriction.

Dietary advice for obesity: evidence base is for energy deficit (500–750 kcal/day = 0.5–0.75 kg/week loss), not specific macronutrient restriction. South Asian-specific advice: portion control for rice (not elimination), replace refined grains with wholegrain, eliminate liquid calories (SSBs, fruit juice, full-cream chai), increase dietary fibre and legumes. Cultural competence: never advise elimination of staple foods without a culturally acceptable substitute.

The evidence base for dietary weight loss is unequivocal: total caloric deficit drives weight loss, not any specific macronutrient pattern. A 500–750 kcal/day deficit from any source achieves clinically meaningful weight loss. Eliminating rice is often harmful to adherence in South Asian patients (rice is a cultural staple); the advice should be portion control, not elimination. Eliminating fruit juice (option C) addresses a high-calorie-density specific item and is excellent practical advice — but is not the answer with the strongest overall evidence base for the intervention.